A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
about
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.Formalizing an integrative, multidisciplinary cancer therapy discovery workflowHigh dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors.CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory NeuroblastomaUse of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of GliomaA phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.The SK-N-AS human neuroblastoma cell line develops osteolytic bone metastases with increased angiogenesis and COX-2 expression.Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model.Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settingsA systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.Molecular biology of pediatric brain tumors and impact on novel therapies.Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors.Review of low-grade gliomas in children--evolving molecular era and therapeutic insights.Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.Physiological, Tumor, and Metastatic Niches: Opportunities and Challenges for Targeting the Tumor Microenvironment.Myxopapillary ependymomas in children: imaging, treatment and outcomes.Fenofibrate subcellular distribution as a rationale for the intracranial delivery through biodegradable carrier.Fenofibrate enhances barrier function of endothelial continuum within the metastatic niche of prostate cancer cells.Advances in emerging drugs for the treatment of neuroblastoma.Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.Commentary on: "A Multi-Institutional Experience in Pediatric High Grade Glioma".Metronomic therapy can increase quality of life during paediatric palliative cancer care, but careful patient selection is essential.Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical Teratoid Rhabdoid Tumor: A Case Report.Geminin deficiency enhances survival in a murine medulloblastoma model by inducing apoptosis of preneoplastic granule neuron precursors.Association between nonsteroidal anti-inflammatory drugs use and risk of central nervous system tumors: a dose-response meta analysis.Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of care.A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma.EANO guidelines for the diagnosis and treatment of ependymal tumors.Antiangiogenic therapy for primitive neuroectodermal tumor with thalidomide: A case report and review of literature.Utility of MRI versus tumor markers for post-treatment surveillance of marker-positive CNS germ cell tumors.Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study.In Vitro Assays for Endothelial Cell Functions Required for Angiogenesis: Proliferation, Motility, Tubular Differentiation, and Matrix Proteolysis.Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical TrialChemical modulation of autophagy as an adjunct to chemotherapy in childhood and adolescent brain tumors
P2860
Q33618884-C9A9C87C-1518-4751-8A00-074C245D0665Q33693626-B6A77FC8-D147-4744-A8E2-E93B4B02B9D6Q34091419-7252043A-C276-44AE-91CA-03643E6549C5Q34437996-1D0DC639-321B-472A-98EC-C7E0A613AEBCQ34543413-DF7A39D4-3AC2-4DAC-AA91-4B2686121DEBQ35644191-3E3282CE-333F-4F27-856F-6CDE30D37A9DQ35922107-F8D2A16C-6A0B-49BB-98A1-6A7B28D444B7Q36031619-717E46EE-1124-4317-B220-A05EDC281FDCQ36492336-C2F9FC6D-EF71-45B5-8F9F-92EFFFD91975Q36772203-D4959E1F-A0D8-4FBE-AC1A-DCBF2C5E01C3Q37086200-B33A1B76-72B5-46E0-BD3B-1A8C1DEB3F0EQ37458763-7B66FC8A-44A3-4950-B5B6-ED116B1D679BQ37461968-A76C3EBB-F623-4958-9D99-017C2730242AQ38249998-0E655B7B-DC94-4C66-A780-C6F2F197C264Q38359284-E515416D-0CA6-4699-AE05-DF93F893D08AQ38363549-6DCED020-58B1-44E2-A7D0-135FA06D2E8AQ38365733-00DAFD88-A071-4636-A6EB-34850EB3B891Q38378439-7E5ED9BE-AFCF-46AA-A64C-B86BDE5938ABQ38582873-D75A9725-EFF3-4223-AD60-56DF91C4B0C1Q38607486-C1B49251-2CDB-4066-8C10-D21C18818B75Q38883374-75454673-DE82-4AAC-8FD6-9602F2CC596EQ38941022-DCB58DED-6BD3-4D68-A043-9A4439EF8E75Q39158415-7A896DE0-6C24-407F-8944-917E16FCBBCBQ39217689-635A60E5-3E6D-47F5-9788-98E8F2AE6E0EQ39376191-091FA936-340D-42D8-83D9-82C152C1E0AFQ40956493-14CCE2BE-67B0-484E-989D-D6C039E0CAF0Q42420669-D6208867-2F4B-4DD3-A673-5AF98FA5A716Q46127435-35138E0C-953D-49D7-A5D5-70C1C54BA5A1Q47115561-7B1BBB9B-685D-4FF8-8BAA-48B128C3F5B6Q47127252-D66ECD0B-B8E1-4487-AC6A-78595EC05977Q47133403-C1D7CD27-6D64-4B0D-B7E7-42A3765940E1Q47296254-640C2D8D-5696-48F4-85EF-28AAE4267254Q47756231-A438293B-44D6-4E7D-ADFD-41B0CAF72659Q47940473-3ADAA416-5B90-4BCE-BD9C-0D798964BD3BQ49452336-341A1DA3-A025-467C-9CC3-17E9017FCA9DQ51645948-B3BEE826-0138-44F6-AB1C-E798A477F806Q51708755-0943375D-E458-4222-89E3-2308606BB4D7Q53097666-78309F74-E055-4B37-B3B7-8AEF13883E41Q57490984-F8A22EE1-D4D6-4838-B440-69058C361334Q59133202-A389EC79-E54A-47D0-B561-41DB8F325C36
P2860
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A phase II trial of a multi-ag ...... current or progressive cancer.
@ast
A phase II trial of a multi-ag ...... current or progressive cancer.
@en
A phase II trial of a multi-agent oral antiangiogenic
@nl
type
label
A phase II trial of a multi-ag ...... current or progressive cancer.
@ast
A phase II trial of a multi-ag ...... current or progressive cancer.
@en
A phase II trial of a multi-agent oral antiangiogenic
@nl
prefLabel
A phase II trial of a multi-ag ...... current or progressive cancer.
@ast
A phase II trial of a multi-ag ...... current or progressive cancer.
@en
A phase II trial of a multi-agent oral antiangiogenic
@nl
P2093
P2860
P356
P1476
A phase II trial of a multi-ag ...... ecurrent or progressive cancer
@en
P2093
Anne E Bendel
Annette M Werger
Christine A Chordas
Christopher D Turner
Donna S Neuberg
Federico Campigotto
Jay B Pietrantonio
Joshua B Rubin
Laura Kondrat
Mary Ann Zimmerman
P2860
P304
P356
10.1002/PBC.24794
P577
2013-10-04T00:00:00Z